🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Team work, Erick Saldanha, MD and Ian Hirsch Some very welcome changes in the treatment landscape of advanced uveal melanoma patients in the recent years and the heterogeneity of resources across different healthcare systems make “perspective” papers, such as this one, essential.

#CTOS2025 registration and abstract submission system is open! 🎉Don't miss the biggest #sarcoma meeting and unique celebration of CTOS's 30th anniversary! 🗓️ We are waiting for your abstracts until Jun 20th! More details on the meeting website ⏩ ctos.org/Meeting/2025An…

It has been unclear why cancer patients with CH have worse outcomes. Our work published NEJM uncovers that Tumor infiltrating CH (TI-CH) has a direct role in immune remodelling of the TME with implications for tumor progression & treatment response. Memorial Sloan Kettering Cancer Center The Crick

Impact and safety of pregnancy on desmoid fibromatosis management in the era of active surveillance. An international multicenter retrospective observational study - European Journal of Cancer ejcancer.com/article/S0959-…

EP300::VGLL3 #rhabdomyosarcoma: a potential distinct indolent adult RMS subtype 🚨Think of this emerging subtype if: ✔️Male, aged 30-60 ✔️ Spindle cell / sclerosing #RMS 👅 of the tongue 🙌🏻 Appear indolent with good outcomes in all reported cases esmorarecancers.org/article/S3050-

Please join me in the Trainee & Early Career Lounge Located in Hall C for specialized programming, complimentary refreshments, and a comfortable space to relax for Student, Resident, Fellow, and Early Career Oncologists. #ASCO25 ASCO Sylvester Comprehensive Cancer Center

Brilliant presentation of the placebo-controlled Ph3 trial MANEUVER by Dr Gelderblom. CSF1R inhibitor Pimicotinib provided statistically significant/clinically meaningful improvement in pain and functionality for #TGCT pts, with manageable toxicity profile (and no signs of

Provoking data of off-label trastuzumab-deruxtecan (T-DXd) use in pts with advanced/refractory desmoplastic small round cell tumor. No clear association between mRNA expression/IHC staining with responses though. #ASCO25 Moffitt Cancer Center

Encouraging activity of abemaciclib in KS pts, with 84% response rate and no significant impact in CD4+ T-cell counts. Great to see how CDK4/6i are entering the sarcoma field, and good to have long-term safety/management data generated by our breast cancer med onc colleagues.

Key take-away points raised by Dr Andrew Wagner from Dana-Farber on the unique challenges we still face in the development and access to therapy for ultra-rare sarcoma pts. The PUSH platform will be an important tool to enable a better understanding and broaden access to

At #ASCO25, Tiago Biachi, MD, PhD (Tiago Biachi), caught up with Richard Kim, MD, to discuss top GI cancer studies and what they mean for the future of patient care. #MoffittASCO25 ASCO

From #ASCO25, Kedar Kirtane, MD (Kedar Kirtane, MD) shares early-phase data from DENALI-1, a study of A2B395—a logic-gated, allogeneic CAR T targeting EGFR in solid tumors with HLA LOH. This novel off-the-shelf approach aims to expand CAR T therapy safely into solid tumors.

Enjoying #ASCO25 so far! Congrats to Andrew Brohl on his oral presentation on neoadjuvant lenvatinib + pembrolizumab in MCC. Results highlight the potential for new combination therapies and biomarkers. We also filmed a chat about exciting sarcoma breakthroughs! #MoffittASCO25

Waack: Lula traz chinês e apressa STF para regular redes; assista #WW

Maybe one day we will have this in MLS.

🚨 New episode of #TheImmunoVerse podcast is live! I had the honor of speaking with James Mule’, a true pioneer in cell therapy and cancer immunology Moffitt Cancer Center. In this episode, he talks about carrying immunotherapy, particularly T cell therapy, from skepticism to standard

Sarcoma Awareness Month shines a light on #sarcoma. On July 25, landmarks around the US and Canada so far will glow yellow for Light Up for Sarcoma! See the graphic for confirmed locations. If you'd like to see a local landmark participate, please connect with them about lighting

Rare sarcomas need real-world data. CURE ID lets you submit treatment experiences that could guide future care. Funded by FDA’s Oncology Center of Excellence. U.S. FDA NIH NCATS Share now at cure.ncats.io/create/case/th…

It is with more sadness than mere words can convey that we have to report that our beloved Ozzy Osbourne has passed away this morning. He was with his family and surrounded by love. We ask everyone to respect our family privacy at this time.   Sharon, Jack, Kelly, Aimee and